Acetazolamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Acetazolamide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
221
Registered trials
67
Result records
31
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Acetazolamide can convert its Small molecule drug profile and CAs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Acetazolamide (query alias: acetazolamide) |
|---|---|
| Modality / target | Small molecule drug; CAs; CAs inhibitors |
| Highest global status | Approved |
| Originator | Wyeth Holdings LLC |
| Active developers | Phebra Pty Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Anhui Medical University |
The MCP disease footprint includes Acute angle-closure glaucoma, Glaucoma, Open-Angle, Secondary glaucoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07593612 | Phase 4 | Not yet recruiting | 60 | Total Urinary Sodium Excretion at 6 Hours |
| NCT07469722 | Phase 2/3 | Not yet recruiting | 128 | Pairwise Comparisons With Wins of Clinical Benefit, a Composite of In-Hospital Mortality, Hospital Length of Stay, Absence of Congestion on DUCS at Discharge, and BNP Reduction From Admission to Day 7 or Discharge. |
| NCT07517068 | Early Phase 1 | Active, not recruiting | 19 | Distributions of circulating immune cell subsets. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial
Phase 2; n=50; evaluation: Negative. Reported fields: AE = 60.0 % ; AE = 80.0 %
Acetazolamide to prevent ventilatory drive withdrawal in REM sleep apnoea: a randomised controlled trial
Phase 2; n=11; evaluation: Positive. Reported fields: Collapsibility = 1.8 L/min ; Collapsibility = 1.2 L/min
Nocturnal cerebral oxygenation in patients with COPD at altitude: data from a randomized clinical trial of acetazolamide
Phase 2; n=43; evaluation: Positive. Reported fields: CTO = When ascending from 760 to 3100 meters taking placebo (N=17), CTO and SpO2 decreased from 66.5±1.0% to 63.4±1.0% (P<0.05) and from 90.8±0.4% to 83.7±0.4% (P<0.05), respectively; cerebral (cODI) and arterial (aODI) oxygen desaturation indices (≥4% dips in CTO or SpO2, respectively) increased by a mean(95%CI) of 6.2/h (4.0 to 8.5) and 19.5/h (13.2 to 25.9); (P<0.05). Compared to placebo, the mean CTO (+2.3% [2.2 to 2.5]) and SpO2 (+2.1% [2.1 to 2.2]) were higher and the mean cODI (-4.4/h [-7.3 to -1.5]) and aODI (-15.0/h [-23.1 to -6.9]) were lower in the acetazolamide group, P<0.05 all effects. % ; CTO = 2.3 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Acetazolamide addresses Acute angle-closure glaucoma, Glaucoma, Open-Angle, Secondary glaucoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 31 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CAs records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals | Approved | Financial terms not disclosed |
| 2026-03-24 | Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109 | Approved | US$100.0M stated total |
| 2025-12-17 | EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort® | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Bilayer tablet of dapsone and acetazolamide for treatment of severe burn”. The milestone feed surfaced a patent-application signal described as “Method of pharmaceutical composition comprising acetazolamide for retinal protection and analysis”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising acetazolamide for retinal protection and methods thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
